Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irbesartan and Amlodipine in Essential Hypertension
NCT05476354Phase 3Completed
- Sponsor
- Handok
- Start
- Jul 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of irbesartan + amlodipine in essential hypertension (3 arms), sponsored by Handok. Primary endpoint: Change from baseline in mean sitting systolic blood pressure at 8 weeks. Started Jul 2022; status: completed.
02
Drugs
irbesartan + amlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT05476354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05476354.